These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30980702)

  • 1. Characterization of Disulfide Bond Rebridged Fab-Drug Conjugates Prepared Using a Dual Maleimide Pyrrolobenzodiazepine Cytotoxic Payload.
    Ruddle BT; Fleming R; Wu H; Gao C; Dimasi N
    ChemMedChem; 2019 Jun; 14(12):1185-1195. PubMed ID: 30980702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
    White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
    MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
    Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
    Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridging disulfides for stable and defined antibody drug conjugates.
    Badescu G; Bryant P; Bird M; Henseleit K; Swierkosz J; Parekh V; Tommasi R; Pawlisz E; Jurlewicz K; Farys M; Camper N; Sheng X; Fisher M; Grygorash R; Kyle A; Abhilash A; Frigerio M; Edwards J; Godwin A
    Bioconjug Chem; 2014 Jun; 25(6):1124-36. PubMed ID: 24791606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers.
    Gregson SJ; Barrett AM; Patel NV; Kang GD; Schiavone D; Sult E; Barry CS; Vijayakrishnan B; Adams LR; Masterson LA; D'Hooge F; Snaith M; Harper J; Hartley JA; Howard PW
    Eur J Med Chem; 2019 Oct; 179():591-607. PubMed ID: 31279293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates.
    Pei Z; Chen C; Chen J; Cruz-Chuh JD; Delarosa R; Deng Y; Fourie-O'Donohue A; Figueroa I; Guo J; Jin W; Khojasteh SC; Kozak KR; Latifi B; Lee J; Li G; Lin E; Liu L; Lu J; Martin S; Ng C; Nguyen T; Ohri R; Lewis Phillips G; Pillow TH; Rowntree RK; Stagg NJ; Stokoe D; Ulufatu S; Verma VA; Wai J; Wang J; Xu K; Xu Z; Yao H; Yu SF; Zhang D; Dragovich PS
    Mol Pharm; 2018 Sep; 15(9):3979-3996. PubMed ID: 30040421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
    Gregson SJ; Masterson LA; Wei B; Pillow TH; Spencer SD; Kang GD; Yu SF; Raab H; Lau J; Li G; Lewis Phillips GD; Gunzner-Toste J; Safina BS; Ohri R; Darwish M; Kozak KR; Dela Cruz-Chuh J; Polson A; Flygare JA; Howard PW
    J Med Chem; 2017 Dec; 60(23):9490-9507. PubMed ID: 29112410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SEC-MS in denaturing conditions (dSEC-MS) for in-depth analysis of rebridged monoclonal antibody-based formats.
    Benazza R; Koutsopetras I; Vaur V; Chaubet G; Hernandez-Alba O; Cianférani S
    Talanta; 2024 May; 272():125727. PubMed ID: 38364570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attachment Site Cysteine Thiol pK
    Vollmar BS; Wei B; Ohri R; Zhou J; He J; Yu SF; Leipold D; Cosino E; Yee S; Fourie-O'Donohue A; Li G; Phillips GL; Kozak KR; Kamath A; Xu K; Lee G; Lazar GA; Erickson HK
    Bioconjug Chem; 2017 Oct; 28(10):2538-2548. PubMed ID: 28885827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.
    Kumar A; Kinneer K; Masterson L; Ezeadi E; Howard P; Wu H; Gao C; Dimasi N
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3617-3621. PubMed ID: 30389292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
    Pillow TH; Schutten M; Yu SF; Ohri R; Sadowsky J; Poon KA; Solis W; Zhong F; Del Rosario G; Go MAT; Lau J; Yee S; He J; Liu L; Ng C; Xu K; Leipold DD; Kamath AV; Zhang D; Masterson L; Gregson SJ; Howard PW; Fang F; Chen J; Gunzner-Toste J; Kozak KK; Spencer S; Polakis P; Polson AG; Flygare JA; Junutula JR
    Mol Cancer Ther; 2017 May; 16(5):871-878. PubMed ID: 28223423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.
    Bryant P; Pabst M; Badescu G; Bird M; McDowell W; Jamieson E; Swierkosz J; Jurlewicz K; Tommasi R; Henseleit K; Sheng X; Camper N; Manin A; Kozakowska K; Peciak K; Laurine E; Grygorash R; Kyle A; Morris D; Parekh V; Abhilash A; Choi JW; Edwards J; Frigerio M; Baker MP; Godwin A
    Mol Pharm; 2015 Jun; 12(6):1872-9. PubMed ID: 25894424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and testing of engineered multimeric Fabs of trastuzumab.
    Selis F; Sandomenico A; Cantile M; Sanna R; Calvanese L; Falcigno L; Dell'Omo P; Esperti A; De Falco S; Focà A; Caporale A; Iaccarino E; Truppo E; Scaramuzza S; Tonon G; Ruvo M
    Int J Biol Macromol; 2020 Dec; 164():4516-4531. PubMed ID: 32941911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates.
    Staben LR; Chen J; Cruz-Chuh JD; Del Rosario G; Go MA; Guo J; Khojasteh SC; Kozak KR; Li G; Ng C; Lewis Phillips GD; Pillow TH; Rowntree RK; Wai J; Wei B; Xu K; Xu Z; Yu SF; Zhang D; Dragovich PS
    J Med Chem; 2020 Sep; 63(17):9603-9622. PubMed ID: 32787101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
    Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
    Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
    Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative binding of disulfide-bridged PEG-Fabs.
    Khalili H; Godwin A; Choi JW; Lever R; Brocchini S
    Bioconjug Chem; 2012 Nov; 23(11):2262-77. PubMed ID: 22994419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrocyclic pyrrolobenzodiazepine dimers as antibody-drug conjugate payloads.
    Donnell AF; Zhang Y; Stang EM; Wei DD; Tebben AJ; Perez HL; Schroeder GM; Pan C; Rao C; Borzilleri RM; Vite GD; Gangwar S
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5267-5271. PubMed ID: 29102228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.